Showing 241 - 260 results of 148,419 for search '(( 5 non decrease ) OR ((( 10 ((we decrease) OR (a decrease)) ) OR ( 2 step decrease ))))', query time: 0.82s Refine Results
  1. 241
  2. 242
  3. 243

    Effect of iron mining tailings as a red ceramic additive for decreased sintering temperature by Igor Brumano Coelho Amaral (10472061)

    Published 2021
    “…We produced test pieces including a mixture of soil with 10 and 20% content of waste exposed to the sintering process at temperatures of 750, 850 and 950° C. …”
  4. 244
  5. 245
  6. 246
  7. 247

    Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

    Published 2025
    “…<p><b>A.</b> Representative traces of potassium currents evoked with 10 mV potential steps from −70mV to +60 mV in PFC PV interneurons from control (black) and cuprizone (red) mice. …”
  8. 248
  9. 249

    Table_1_Soil Properties Interacting With Microbial Metagenome in Decreasing CH4 Emission From Seasonally Flooded Marshland Following Different Stages of Afforestation.xlsx by Qian Zhang (49333)

    Published 2022
    “…Compared to the non-afforested land use types, net CH<sub>4</sub> emission decreased from bare land, natural vegetation and 5-year forest plantation and transitioned to net CH<sub>4</sub> sinks in the 10- and 20-year forest plantations. …”
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257

    Image10_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…”
  18. 258
  19. 259

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  20. 260